Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04449198 · ClinicalTrials.gov registry record · Early Phase 1
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
A Early Phase 1 study of Type 1 Diabetes, sponsored by Augusta University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04449198: Recruiting Early Phase 1 study of Type 1 Diabetes, sponsored by Augusta University.
NCT04449198 is a Early Phase 1 study of Type 1 Diabetes that is actively recruiting participants, run by Augusta University. The registered enrollment target is 24 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04449198, a Early Phase 1 study of Type 1 Diabetes, is actively recruiting participants, sponsored by Augusta University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
Primary Outcome
Change in Area Under the Curve (AUC) for Cutaneous Vascular Conductance (CVC) in response to co-perfusion of ET-1 + BQ-123 at 12 weeks. Measured using intradermal microdialysis technique in conjunction with Laser Speckle Contrast Imaging (Moor FLPI-2) and beat-by-beat blood pressure monitoring (Finapres NOVA).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Resveratrol
Study Locations (1)
Georgia
- Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2027-07-01 |
| Phase | Early Phase 1 |
What NCT04449198 shows while recruiting
NCT04449198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04449198 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT04449198 about?
NCT04449198 is a clinical study titled "Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1". The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
What is the current status of trial NCT04449198?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2020-10-14. Estimated completion is 2027-07-01.
What conditions does trial NCT04449198 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT04449198?
The interventions under investigation include: Placebo (OTHER), Resveratrol (DRUG).
Who is sponsoring clinical trial NCT04449198?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04449198 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04449198's enrollment target sits among peer trials
24 141st of 198 higher than 51 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
RECRUITING · Early Phase 1
-
Effect of C-peptide on Hypoglycemic Counterregulation
RECRUITING · Early Phase 1
-
Adrenergic System in Islet Transplantation
ACTIVE NOT RECRUITING · Early Phase 1
-
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
COMPLETED · Early Phase 1
-
Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy
COMPLETED · Early Phase 1
-
Early Markers of Disease and Response to Therapy
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI